SECONDARY AML

Clinical trials for SECONDARY AML explained in plain language.

Never miss a new study

Get alerted when new SECONDARY AML trials appear

Sign up with your email to follow new studies for SECONDARY AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Experimental drug offers hope for tough blood cancers

Disease control Not yet recruiting

This early-stage study is testing a new drug called rebecsinib in patients with two types of advanced blood cancers: secondary acute myeloid leukemia that has returned or not responded to treatment, and higher-risk myelofibrosis. The main goals are to find the safest dose and see…

Matched conditions: SECONDARY AML

Phase: PHASE1 • Sponsor: Aspera Biomedicines, Inc. • Aim: Disease control

Last updated Apr 01, 2026 14:41 UTC

SECONDARY AML

Get alerted when new SECONDARY AML trials appear

Experimental drug offers hope for tough blood cancers